Kornimate/medical-research-clean huggingface dataset:
arterial spin label depicted ischemic stroke cohort (aslis)

Conditions: Acute Ischemic Stroke

Summary: establish a clinical cohort of acute ischemic stroke patients and find the determinant of the prognosis.

1. enrollment: screening the candidates based on the inclusion and exclusion criteria, and sign the informed consent. 2. baseline evaluation: evaluate baseline situation of enrolled candidates. 3. inpatient view: view and evaluate enrolled candidates respectively at day 1, 3, 7 and 14 after stroke, and record the results. 4. follow-up: view the candidates at 90 days and one year after stroke onset, and record the results. 5. data analysis: analyze the results.

Eligibility criteria:
inclusion criteria: 1. age 30-90, no gender restrictions. 2. onset of disease ≤7 days. 3. meet either of the following two conditions: ① transient ischemic attack (tia) ② ischemia stroke (is) note: acute is diagnosis criteria: sudden and persistent focal or widespread neurological dysfunction, excluding other non-vascular causes of brain dysfunction (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases), confirmed by image as new is. tia diagnosis criteria: sudden and reversible focal neurological or retinal ischemic deficit caused by a reversible ischemia, usually lasting less than 24 hours, with no evidence of new is on imaging, and excluding other non-ischemic causes (such as brain infection, head injury, brain tumor, epilepsy, severe metabolic diseases, or degenerative neurological diseases). 4. signed informed consent exclusion criteria: 1. clear cause of ischemic stroke other than atrial fibrillation. 2. other ischemic strokes with a clear cause. 3. presence of non-vascular intracranial disease. 4. presence of severe systemic diseases. 5. pregnancy or lactation. 6. unable to tolerate or cooperate with mri examination. 7. unable to comply with follow-up due to geographical or other reasons.

Keywords: acute ischemia stroke, arterial spin labeling, evaluation
walk together: a family-based intervention for hypertension in african americans

Conditions: Hypertension; Family Relations

Summary: the goal of this study is to determine the feasibility and acceptability of a novel family-based hypertension self-management intervention, walk together, adapted from an existing empirically-supported dyadic intervention, for implementation in primary care.

hypertension is the driving risk factor for disparities in mortality and life expectancy between african americans and whites. hypertension self-management (including blood pressure monitoring, diet, exercise, and other lifestyle changes) is critical for improving hypertension control, and prior interventions have emphasized promoting patient-level behavior change to improve self-management adherence. though family members make substantial contributions to hypertension self-management for african americans, family support is consistently underutilized by current hypertension self-management interventions. family-based interventions for improving self-management are effective for other chronic conditions, including for african americans. evidence has demonstrated the unique and important role of family support in african americans' hypertension management, and african americans' preferences for the direct involvement of family in hypertension interventions. the study team will develop a family-based hypertension self-management intervention ("walk together") for african americans with uncontrolled hypertension that integrates community-based participatory perspectives in the specifics of the intervention. the study team will pilot trial the culturally-adapted intervention in a primary care setting in order to examine the feasibility and acceptability of the walk together protocol.

Eligibility criteria:
inclusion criteria: * black or african american * age 18 to 75 * two blood pressure values ≥ 130/ ≥ 80 in 12 months prior * available family support person to join the intervention who agrees to participate * english-speaking exclusion criteria: * family support person is under the age of 18 * documented cognitive impairment in patient's medical record * presence of severe psychiatric condition (i.e., current psychotic disorder or suicidality) * participation in prior hypertension health education intervention * prior participation in formative study activities (i.e., study focus groups)

Keywords: family support integrated health care systems healthy lifestyle community-based participatory research african americans
predictive models on pain and severity in fm patients

Conditions: Fibromyalgia

Summary: the primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. as specific objectives the research project intends: to predicting fibromyalgia severity of patients based on clinical variables; to assess the relevance of social-psycho-demographic variables on the fibromyalgia severity of the patients; to predict the pain suffered by the patients as well as the impact of the fibromyalgia on patient's life; to categorize fibromyalgia group of patients depending on their levels of fibromyalgia severity.

fibromyalgia (fm) is a condition characterized by chronic musculoskeletal pain whose pathophysiology is still unclear. furthermore, this pathology is frequently associated with sleep disturbances, pronounced fatigue, morning stiffness, poor quality of life, cognitive disturbances (mainly memory problems) and psychological problems (depression, anxiety and stress). fm is associated with greater negative affect, which implies a general state of anguish composed of aversive emotions such as sadness, fear, anger and guilt. patients with fm commonly suffer from high rates of anxiety, depression, pain catastrophizing, and stress levels, which are associated with a worsening of symptoms, including own cognitive. machine learning (ml) and data mining had been successfully applied, over the past few decades, to build computer-aided diagnosis (cad) systems for diagnosing complex health issues with good accuracy and efﬁciency by recognizing potentially useful, original, and comprehensible patterns in health data. thus, machine learning provides useful tools for multivariate data analysis allowing predictions based on the established models and hence offering a suitable advantage for risk assessment of many diseases including heart failure. machine learning offers advantages not only for clinical prediction but also for feature ranking improving the interpretation of the outputs by clinical professionals. explainable ml models, also known as interpretable ml models, allow healthcare experts to make reasonable and data-driven decisions to provide personalized treatment that can ultimately lead to high quality of service in healthcare. these models fall into explainable artificial intelligence (xai) field, defined as suite of ml techniques that 1) produce more explainable models while maintaining a high level of learning performance, and 2) enable humans to understand, appropriately trust, and eﬀectively manage the emerging generation of artiﬁcially intelligent partners.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * fullfilled the 2010 american collegue of rheumathology criteria for fibromyalgia. * understanding of spoken and written spanish. exclusion criteria: * diagnosed psychiatric pathology. * rheumatic pathology not medically controlled. * neurological pathologies that make evaluations difficult.
study of lonafarnib and gleevec in chronic myelogenous leukemia

Conditions: Chronic Myelogenous Leukemia

Summary: the purpose of this study if to investigate the effect of lonafarnib (sch66336) in combination with gleevec in the treatment of cml.

existing pre-clinical and clinical data suggest that sch66336, a farnesyl transferase inhibitor,exhibits significant activity against cml cells, and in fact may have synergistic activity in combination with imatinib mesylate. thus, the objectives to the study are (1) to determine the maximum tolerated dose (mtd) and dose limiting toxicities (dlt) of lonafarnib (sch66336), a farnesyl transferase inhibitor, in combination with imatinib mesylate (gleevec) in patients with chronic phase, accelerated phase, and blast crisis cml; (2) to assess the pharmacokinetics of the combination of lonafarnib and gleevec in these patients; and (3) to assess in a preliminary way the biologic activity of the combination of lonafarnib and gleevec in these patients.

Eligibility criteria:
1. patients with philadelphia chromosome (ph) positive cml in any of the following categories: 1. chronic phase patients must have failed therapy with gleevec. failure will be defined as: (i) patients who have not achieved or have lost their hematologic response at 3 months from the start of therapy with gleevec, or (ii) patients who have not achieved or have lost their cytogenetic response after 6 months of therapy with gleevec, or (iii) patients who have not achieved or have lost their major cytogenetic response after 12 months of therapy with gleevec. 2. patients in accelerated phase, defined as the presence of any of the following features: (i) blasts in peripheral blood (pb) or bone marrow (bm) \>/= 15% (but \ /= 30%, (iii) basophils in pb or bm \>/= 20%, (iv) platelets \< 100 x 10e9/l unrelated to therapy, (v) clonal evolution. 3. patients in blast phase, defined by the presence of \>/= 30% blasts in peripheral blood and/or bone marrow, or the presence of extramedullary disease. 2) patients in accelerated or blastic phase are eligible whether they have received and/or failed gleevec or not. 3) age \>/= 16 years. 4) patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping eith the policies of the hospital. the only acceptable consent form is attached at the end of the protocol. 5) performance status \</= 2 by zubrod scale. 6) patients must have adequate hepatic functions (bilirubin \</= 2.0 mg/dl) and renal functions (creatinine \</= 2 mg/dl). 7) exclusion criteria: 1. patients with qtc \> 500 msec. 2. patients with severe heart disease (cardiac class iii and iv) will be excluded.
autologous serum skin test and serum il-18 levels in chronic idiopathic urticaria and respiratory allergic diseases

Conditions: Urticaria; Respiratory Allergic Diseases

Summary: one of the proposed mechanisms in cu is autoimmunity. it was shown by a positive response to autologous serum skin test (asst)in almost half of chronic urticaria (cu) patients. il-18 also play a role in autoimmune disorders. the investigators aim was to investigate the relationship of asst and il-18 in cu and respiratory allergic diseases.


Eligibility criteria:
inclusion criteria: * adult patients * chronic urticaria patients * stable asthma patients * allergic rhinitis patients with sensitized to pollens * normal controls without atopic and skin disease. exclusion criteria: * unwillingness to the study * other dermatological problems that could affect the skin test * use of antihistamine drugs

Keywords: autologous serum skin test, il-18
exercise in autoimmune myasthenia gravis and myasthenic syndromes

Conditions: Autoimmune Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic Syndrome; Myasthenia Gravis

Summary: a few recent observational studies show that despite the lack of clear recommendations, many individuals with myasthenia participate in exercise. however, no link has been found between exercise and the severity of myasthenia symptoms, measured by the muscle myasthenia score or the myasthenia gravis composite score. this suggests that there are other factors that may limit or prevent some individuals from being active, or factors which may facilitate participation in exercise. studies in other diseases have shown that there are internal (beliefs, motivation, etc.) and external (cost, accessibility, etc.) factors unrelated to the disease which may play a role in exercise participation. the aim of this study is to identify factors that facilitate or limit exercise in individuals with autoimmune myasthenia gravis, congenital myasthenia syndrome and lambert-eaton syndrome.


Eligibility criteria:
inclusion criteria: * at least 18 years old * confirmed diagnosis of mg or smc or lems * live in france or its territories * provide consent exclusion criteria: -
accountability support through peer-inspired relationships and engagement (aspire) trial

Conditions: Alcohol Consumption

Summary: this project aims to test the efficacy of a text message intervention, aspire, designed to address cognitive and behavioral elements and modify exposure to peers that influence drinking behaviors. young adults who are contemplating reducing their drinking will be recruited from a national sample and randomized to aspire versus a text message intervention focused solely on cognitive and behavioral elements. we will measure effectiveness at 3, 6, and 12 months, study mechanisms driving behavior change, and identify which subgroups stand to benefit most.


Eligibility criteria:
inclusion criteria: * age 18-25 years (verified using date of birth) * lives in the u.s. (based on zip code) * english reader (verified based on completing screen) * 2+ days with ≧4 standard alcohol drinks for women or ≧5 standard alcohol drinks for men in past month * owns a mobile phone with sms (verified by texting enrollment procedure) exclusion criteria: * currently enrolled or past enrollment in a 4-year college * active military * pregnant or pregnancy plans in the next 12-months * prisoner status * current or planned treatment for alcohol or substance use disorder in next 12-months

Keywords: alcohol text message young adults peers
effect of a new growing-up milk on growth and nutrient adequacy in children with picky-eating behaviors

Conditions: Picky Eating Behaviors

Summary: the primary objective of the study was to compare the change in z-scores for growth during a 120-day study period in children with picky eating behaviors who were randomly assigned to receive nutrition counseling only (control group) or nutrition counseling plus an oral milk-based nutritional supplement (study group). the secondary objectives of the study were to compare the following between the control and study groups: a) dietary macro- and micro-nutrient intakes; b) quantitative ultrasound bone measurements of radius and tibia; and c) incidence of common illnesses (diarrhea, upper and lower respiratory tract). the safety objective of the study was to compare the frequency of adverse events (ae) among the control group and study group subjects.


Eligibility criteria:
inclusion criteria: * children aged 30-60 months with pe behavior as reported by caregivers and whose weight-for-height was ≤25th percentile according to world health organization (who) child growth standards were eligible for inclusion. exclusion criteria: * current acute or chronic illness, food allergies, lactose intolerance, dietary restrictions precluding dairy foods, any genetic disorder that may compromise growth and/or food intake, cognitive or developmental disorders, or medications that may influence study outcomes.

Keywords: children with picky-eating behaviors children aged 2.5 - 5 years reported by caregivers with weight-for-height z-scores ≤ 25th percentile at enrollment
clinical evaluation of genetron tert pcr kit in glioma patients

Conditions: Glioma, Malignant

Summary: the purpose of this trail is to evaluate the performance of genetron tert pcr kit in glioma patients using real-time pcr method.

this trial follows the principle of synchronous blinding. the enrolled cases are coded, and the enrolled samples are detected with the genetron tert pcr kit and sanger sequencing method. the results were determined independently according to the cutoff values or interpretation requirements provided by each method.combined with the results of clinicopathological classification, the incidence of c228t and c250t mutations of tert promoter genes in different subtypes was counted to evaluate the clinical application performance of the genetron tert pcr kit.

Eligibility criteria:
inclusion criteria: 1. enroll cases in strict accordance with the requirements of the study 2. the remaining samples after routine clinical testing 3. the collection and processing of samples meet the requirements of standard laboratory operations and product instructions 4. the relevant information of the sample is complete, including sample number, gender, age, and possible clinical diagnosis information 5. each sample must have he staining results (hematoxylin-eosin staining) 6. pathological examination diagnosed as glioma, other brain tumors or normal tissues 7. number of samples: 10 pieces of each sample with a thickness of 10μm, and the tumor content is not less than 50% exclusion criteria: 1. the sample information is not complete 2. severely contaminated samples 3. samples that do not meet the requirements of sample collection and processing
grand autohemo-therapy with oxygen-ozone on patients with hypertonia

Conditions: Hypertonia

Summary: the objective of this clinical study is to evaluate the influence of the great autohemotherapy with oxygen-ozone (hyperbaric ozone therapy ) to describe the cardiovascular system in patients with resistant hypertension. the primary endpoint is the change in mean blood pressure after 10 treatments . in addition, data are collected on the immune system as well as for food and sleep quality.


Eligibility criteria:
inclusion criteria: * resistant hypertension \> 140 / \> 90mmhg * inclusion age : 45 + * regular monitoring of blood levels considered * pre-medication to lower blood pressure for at least 3 weeks before the preliminary investigation consistent * men and women exclusion criteria: * derailed diabetes * renal impairment , renal creatinine clear \<50 ml * non - austherapierte cancer / tumor patients * non - adjusted thyroid dysfunction * bmi\> 35 * lvef \<limit ( " 35% " ) * peripheral avk ( abi - measurement ) \> stage ii * regurgitation \> stage i * abdominal aneurysm * infections * acute febrile infections with temperature \> 38.5 ° c * copd and asthma to stage iii * dyspnea nyha \> stage iii * z.n. stroke shorter than 12 weeks * acute liver failure * acute apoplexy * severe poisoning * drug addiction * hyperthyroidism * hypotension * hypocalcemia * hypoglycemia * ozone allergy * pregnancy * clotting problems ( hemophilia ) * pre-existing condition with hemoglobin \< 9mg/dl * fresh myocardial infarction * internal bleeding * thrombocytopenia * acute alcohol * citrus allergy when using sodium citrate
effect of subarachnoid block and femoropopliteal block to limb perfusion in pad patients

Conditions: Peripheral Arterial Disease; Subarachnoid Block; Femoropopliteal Block; Tissue Oxygen Saturation

Summary: this pilot study investigates the effects of femoropopliteal and subarachnoid nerve blocks on tissue oxygen saturation (sto2) in patients with peripheral arterial disease (pad) during lower limb surgeries. using near-infrared spectroscopy (nirs), the study compares changes in sto2 post-block. although no significant differences were found between the two block types at most time points, subarachnoid blocks generally led to higher sto2 increases compared to femoropopliteal blocks, with significant differences observed at 5 and 15 minutes post-block.

this pilot study explored the impact of femoropopliteal and subarachnoid nerve blocks on tissue oxygen saturation (sto2) in patients with peripheral arterial disease (pad) during lower limb surgeries, using near-infrared spectroscopy (nirs) for non-invasive monitoring. the study compared sto2 changes at baseline, 5, 15, and 30 minutes post-block in two groups: those receiving femoropopliteal blocks and those receiving subarachnoid blocks.

Eligibility criteria:
inclusion criteria: * age 18-80 years old who are scheduled to undergo lower limb debridement surgery. * diagnosis of peripheral arterial disease (pad). * lesion located below the knee. exclusion criteria: * consuming opioids before hospital admission. * having allergies to the medications used in the study. * presence of infection at the injection site.
troponint after subcutaneous cardioverter-defibrillator implantation

Conditions: Sudden Cardiac Death

Summary: serum troponin levels pre- and postoperatively will be compared in patients receiving an entirely subcutaneous cardioverter-defibrillator.

to analyze the periprocedural myocardial damage the pre- and postoperative assessment of serum levels of high sensitive troponint (hstnt) is done. the main objectives of the tropic register are to evaluate the level of high sensitive troponint before and after s-icd device implantation and to compare these changes in troponint-levels with those after standard transvenous icd-implantation.

Eligibility criteria:
inclusion criteria: * indication for the implantation of an entirely subcutaneous cardioverter-defibrillator exclusion criteria: * none
intra operative continuous laryngeal nerve monitoring during thyroid surgery and interpretation of the post-operative voice quality in relation to the electromyography data obtained during surgery

Conditions: Thyroid Surgery

Summary: during thyroid surgery the laryngeal recurrent nerves (and for this reason the voice quality) are at risk. therefore intra operative continuous neuromonitoring could help to prevent harm to these nerves. electromyographic data (emg values) are collected during surgery (1). in the postoperative follow-up period detailed voice analysis is performed (2): subjective auditive perceptive evaluation and videostroboscopy. analysis and comparison of (1) and (2) will be performed in order to find out if we can find a predictive correlation between the emg data (1) and the voice quality (2).


Eligibility criteria:
inclusion criteria: * patients (men/women) requiring thyroid surgery exclusion criteria: * patients younger than 18 years, patients with preoperative vocal cord anatomical and functional anomalies.

Keywords: thyroid surgery
mean platelet volume and txa2 levels in patients with polycystic ovary syndrome (pcos)

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos)is closely associated with insulin resistance and hyperinsulinemia as well as with increased incidence in diabetes, hypertension, dyslipidemia and atherosclerosis. indeed, subjects with pcos were reported to carry an increased long-term cardiovascular risk, among others. aiming to correlate the mean platelet volume, the thromboxane a2 level and the pcos, an observational study was planned. clinical evaluation of metabolic outcomes in pcos patients is compared to a placebo group.


Eligibility criteria:
inclusion criteria: * women fulfilled two out of three diagnostic criteria for pcos exclusion criteria: * pre-existing secondary endocrine disorders * history of hypertension, diabetes mellitus or cardiovascular disorders * pharmacologic treatment in the last 6 months before entering the study.

Keywords: pcos cardiovascular disorders